 NEWARK, Calif., June 7, 2021 PRNewswire -- Protagonist Therapeutics Nasdaq: PTGX Protagonist or the Company today announced that management will host an investor conference call and webcast to provide a brief corporate update and discuss data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera PV, which was selected as an oral presentation at the European Hematology Association 2021 Annual Congress. 